Stay updated with breaking news from Planegg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
![MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -December 11, 2023 at 10:01 am EST - Vimarsana News](https://www.marketscreener.com/images/twitter_MS_fdblanc.png)
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
The biotech company Morphosys has presented detailed results from its study with its promising drug pelabresib in the treatment of myelofibrosis. In the Phase 3 trial for the treatment of this type of...
EQS-News: MorphoSys AG / Key word(s): Conference MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in...
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Correction of a release from 07.12.2023 according to Article 40, Section 1 of the WpHG [the German Securities Trading...